Feasibility Study of Personalized Hyperthermic Intraperitoneal Chemotherapy Guided by Mass-Based Response Testing for High-Grade Appendiceal and Colorectal Cancer with Peritoneal Metastasis

What this Trial Is About

Researchers are evaluating mass-based response testing MRT to guide personalized hyperthermic intraperitoneal chemotherapy HIPEC for patients with peritoneal metastases from high-grade appendiceal adenocarcinomas and colorectal cancer. This study aims to improve treatment selection for patients who have unresectable disease or extensive cancer spread within the abdomen. The study evaluates whether MRT can help choose effective chemotherapy drugs tailored to the individual patients tumor. Participants with unresectable peritoneal metastases will have tissue biopsies tested with MRT to identify optimal chemotherapy drugs. Those with unresectable disease will receive iterative HIPEC IHIPEC, which combines repeated cycles of heated chemotherapy delivered inside the abdomen with systemic chemotherapy. The IHIPEC cycles start about three weeks after laparoscopy and are repeated approximately three times with six weeks between each treatment. During the study, participants will be monitored for up to 12 months. Researchers will assess the feasibility of using MRT to select personalized HIPEC regimens, overall survival, treatment complications, quality of life, financial impacts, tumor response, and chemotherapy delivery success. Assessments include tissue biopsies, laparoscopy, laboratory tests, and questionnaires every three months. This detailed monitoring helps evaluate the treatment process and its effects over time.

A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis